Sustained Reduction in Tumour Size Seen In Pancreatic Trial
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- First 26 Patients recruited in Phase 2A ACCENT Trial
- Preliminary Final Report and Annual Report YE 31 March 2024
- $4.27m Offer Successfully Completed and ACCENT Trial Update
- Rights Issue Investor Slide Deck
- Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
Later from Amplia Therapeutics
- Additional Patient Response in Pancreatic Cancer Trial
- Granting of Key Patent in Europe and Japan
- Amplia Receives R&D Tax Rebate Totalling $3.2 Million
- Fifth Confirmed Response in ACCENT Trial
- FDA Fast Track Designation for Narmafotinib
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics